Skip to content

The Impact of Rapid Maxillary Expansion on the Nasal Microbiota of Children with Oral Breathing

The Impact of Rapid Maxillary Expansion on the Nasal Microbiota of Children with Oral Breathing

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112875
Enrollment
Unknown
Registered
2025-11-20
Start date
2024-02-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maxillary transverse deficiency (MTD)

Interventions

Healthy control group:None
Mouth-breathing group with insufficient transverse development of the maxilla (RME treatment):None
Group with insufficient transverse maxillary development during nasal breathing (RME treatment):None

Sponsors

School and Hospital of Stomatology, Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1.MTD groups: Diagnosed with maxillary transverse deficiency requiring rapid maxillary expansion (RME) by orthodontic examination. Mouth-breathing subgroup: habitual mouth breathing and upper airway obstruction confirmed or evaluated by an otolaryngologist. Nasal-breathing subgroup: no history of persistent nasal obstruction or mouth breathing. 2.Healthy control group: Normal maxillary transverse development without anterior/posterior crossbite or crowding, no indication for orthodontic treatment, and no habitual mouth breathing or significant nasal obstruction. 3.Written informed consent obtained from parents or legal guardians. 4.Children aged 5–14 years with good general health.

Exclusion criteria

Exclusion criteria: 1.Use of antibiotics, probiotics, or nasal sprays within the past month. 2.History of adenoidectomy, tonsillectomy, or other nasal/nasopharyngeal surgery. 3.Previous orthodontic or airway interventions, including rapid maxillary expansion, oral appliances, or continuous positive airway pressure (CPAP). 4.Craniofacial syndromes or severe chronic systemic diseases. 5.Complete nasal obstruction, nasal septal perforation, or any known acute infection of the nasal cavity, oral cavity, sinuses, or pharynx. 6.Inability to cooperate with examination or absence of valid informed consent.

Design outcomes

Primary

MeasureTime frame
Microbial diversity changes in nasal samples before and after RME;

Countries

China

Contacts

Public ContactLimin Wei

School and Hospital of Stomatology, Wenzhou Medical University

dentwlm@163.com+86 577 88063016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 30, 2026